肿瘤细胞治疗研究
ALL SOURCES
CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy.
在这项II期研究中，TAK-007，一种现成的表达IL-15的同种异体CD19 CAR NK细胞疗法，在经过重度预处理的B细胞淋巴瘤患者中（包括CAR-T治疗后患者）显示出令人鼓舞的缓解率、快速的治疗可及性和优异的安全性，尽管持久性有限。
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
不良事件可控，细胞因子释放综合征限于 1-2 级（11.5%）。
Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.
作为开创性的免疫治疗手段，CAR-T 细胞与NK 细胞（CAR-NK）疗法在治疗多种血液系统恶性肿瘤时已显示出显著的临床疗效。
Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells.
这些数据将 CAR19-GITRL-NK 细胞定位为一种有效的创新策略，将直接肿瘤靶向与主动破坏 Treg 驱动的免疫抑制结合起来，用于治疗 B 细胞白血病和淋巴瘤。
Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia.
这些数据表明 aCD19 CAR NK 细胞作为 BCP-ALL 联合治疗组成部分的潜力，应在临床试验中进一步评估。
Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.
标准一线免疫化疗对约 60% 的 DLBCL 病例有效，而 30-40% 出现复发或难治性疾病，这凸显了亟需更有效的治疗策略。
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a pha
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.
我们观察到高效的单重和多重碱基编辑，导致NK细胞在体外和体内的功能显著增强。
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.
CD19-BBz CAR-NK 细胞可行且治疗上安全，能够在 B 细胞淋巴瘤患者中诱导持久缓解。
Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways.
与共表达 IL-15 的 CAR-NK 细胞相比，共表达 IL-21 的 CAR-NK 细胞在响应 CD19 + Raji 淋巴瘤细胞时，IFN-、TNF- 和 Granzyme B 的产生以及脱颗粒均显著增加，从而在反复肿瘤刺激下表现出增强的细胞毒活性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
